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Abstract
Background—Aberrant expression of microRNA-155 (miR-155) has been implicated in acute
myeloid leukemia (AML) and associated with clinical outcome.
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Procedure—We evaluated miR-155 expression in 198 children with normal karyotype AML
(NK-AML) enrolled in Children's Oncology Group (COG) AML trial AAML0531 and correlated
miR-155 expression levels with disease characteristics and clinical outcome. Patients were divided
into quartiles (Q1–Q4) based on miR-155 expression level, and disease characteristics were then
evaluated and correlated with miR-155 expression.
Results—MiR-155 expression varied over 4-log10-fold range relative to its expression in normal
marrow witha median expression level of 0.825 (range 0.043–25.630) for the entire study cohort.
Increasing miR-155 expression was highly associated with the presence of FLT3/ITD mutations (P
< 0.001) and high-risk disease (P < 0.001) and inversely associated with standard-risk (P = 0.008)
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and low-risk disease (P = 0.041). Patients with highest miR-155 expression had a complete
remission (CR) rate of 46% compared with 82% in low expressers (P < 0.001) with a
correspondingly lower event-free (EFS) and overall survival (OS) (P < 0.001 and P = 0.002,
respectively). In a multivariate model that included molecular risk factors, high miR-155
expression remained a significant independent predictor of OS (P = 0.022) and EFS (0.019).
Conclusions—High miR-155 expression is an adverse prognostic factor in pediatric NK-AML
patients. Specifically, high miR-155 expression not only correlates with FLT3/ITD mutation status
and high-risk disease but it is also an independent predictor of worse EFS and OS.
Keywords
AML; children; miR-155
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1 Introduction
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Pediatric leukemias are the most common childhood cancers in the United States affecting
up to 4,100 children per year. Acute myeloid leukemia (AML) accounts for one fourth of
pediatric acute leukemias, but leads to nearly half of all deaths. AML is a complex and
heterogeneous disease without a unifying disease-causing event.1,2 Genomic alterations,
whether translocations, copy number changes, or somatic mutations contribute to disease
pathogenesis. Currently, initial responses to treatment as well as the presence/absence of
specific cytogenetic abnormalities and gene mutations are used to prognosticate clinical
outcomes and guide therapeutic interventions.3 For example, the following chromosomal
anomalies are routinely used to define AML risk class: t(8;21)(q22;q22), inv(16)(p13.1q22),
t(15;17)(q22;q21)/PML-RARA, 11q23/MLL rearrangements, monosomy 7 and monosomy
5/5q deletions.4 In addition, genomic alterations including FLT3/ITD5 as well as CEBPA6
and NPM1 mutations are also utilized as prognostic markers.7 However, as our
understanding of AML leukemogenesis continues to evolve, there has been an effort to
identify additional epigenetic/genetic alterations of prognostic significance that could be
used for risk-based therapy allocation.
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MicroRNAs (miRNAs or miRs) are small regulatory RNAs that control the protein
expression of tens to hundreds of targets via mRNA degradation or translational repression.8
Aberrant miRNA expression has been implicated in the pathogenesis of many cancers
including AML.9–11 Altered miRNA regulation of gene expression in leukemia disrupts
many mechanisms important for normal hematopoiesis, including cell proliferation,
differentiation, and survival.12–15 Unique miRNA expression profiles have been
demonstrated for specific cytogenetic subsets in AML,16–18 and altered expression of
miR-155, in particular, has been identified as a potential prognostic factor in adult AML.19
In this report, quantitative expression levels of miR-155 in diagnostic specimens from 198
pediatric normal karyotype AML (NK-AML) patients are analyzed and correlated with
clinical characteristics and outcomes.
MiR-155 is encoded by the MIR155HG gene located on chromosome band 21q21.3.
MiR-155 expression is normally induced in hematopoietic stem cells and myeloid progenitor
cells as part of the inflammatory response, under the control of the transcription factors NF-
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κß and AP-1.20 By targeting inflammatory inhibitors, miR-155 regulates the innate immune
response.20–25 Overexpression of miR-155 has been reported in solid tumors like thyroid,
breast, colon, cervical, and lung cancers as well as in chronic lymphocytic leukemia (CLL)
and lymphomas.20,26 MiR-155 is considered an oncomiR, promoting tumorigenesis through
modulating of target genes involved in proliferation, differentiation, and apoptosis.27

2 Methods
2.1 Patients
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AAML0531 is the phase III clinical trial in which patients were randomized to conventional
chemotherapy +/– Gemtuzumab ozogamicin (GO, Mylotarg).28 AAML0531 enrolled 1,022
patients from August 14, 2006 to June 15, 2010, including 233 patients with NK-AML. We
had 198 diagnostic patient specimens available for analysis, which were prospectively
evaluated for miR-155 expression. Normal marrow was obtained from a commercial vendor
(All Cells, Alameda, CA). The institutional review boards of all participating institutions
approved the clinical protocol and the COG Myeloid Disease Biology Committee approved
this research. In accordance with the Declaration of Helsinki, all patients (or guardians on
behalf of the pediatric patients) provided written informed consent for the collection and use
of their biospecimens for research purposes under studies approved by the British Columbia
Cancer Agency Research Ethics Board (Vancouver, BC, Canada) and the Fred Hutchinson
Cancer Research Center Institutional Review Board (FHCRC, Seattle, WA, USA). Clinical
data were de-identified in compliance with Health Insurance Portability and Accountability
Act regulations.
2.2 Methods
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MiR-155 expression levels were determined by using TaqMan quantitative Reverse
Transcription Polymerase Chain Reaction (RT-PCR) kit using commercially available
primers and probes from Life Technologies, Carlsbad, CA (miR-155 Assay# 000480 and
control gene RNU49 Assay# 001006). Specifically, miRNA was extracted from
ficollenriched mononuclear diagnostic marrow specimens. Total RNA was extracted from
thawed untreated bone marrow cells using Trizol purification method. First stand cDNA
synthesis was performed using 100 ng of total RNA in 15 μl of final volume containing 6 μL
of primer Pool, 10× RT buffer, 50 U/μl Multiscribe reverse transcriptase and 20 U/μl RNase
inhibitor in a 96-well plate. Next, real-time PCR was performed using a standard TaqMan
PCR protocol. Specifically, 20 μl PCR reactions included 1 μl of RT product, 1× Universal
TaqMan Master Mix, 1× TaqMan probe, and 8 μl of water in a 96-well plate. All RT-PCRs
were run in duplicate. Raw data were analyzed using StepOne software version 2.2 from
Life Technologies. Expression levels were normalized to control gene expression (i.e.,
RNU49) and standardized to the normal marrow bone marrow using the delta - delta CT
method. miRNA extracted from 10 independent normal bone marrow specimens were
pooled for this analysis. The expression level of RNU49 was stable throughout all patient
specimens. To evaluate the correlation of miRNA expression and disease characteristics, the
patients were divided into four quartiles (Q1–Q4) based on individual miR-155 expression
levels, where Q1 consisted of those with the lowest miR-155 expression levels and Q4
consisted of patients with the highest miR-155 expression levels. Expression of miR-155
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was correlated with disease characteristics, clinical response, and outcomes across these
quartiles. All comparisons and data presented compares high (Q4) versus low (Q1–Q3)
expressers.
2.3 Risk stratification
Low-risk patients included those with NPM1 or CEBPA mutations. Patients were classified
as high risk if they had FLT3/ITD mutations.
2.4 Statistical methods
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Clinical outcome data for COG AAML0531 were analyzed. Patients were defined as being
in complete remission (CR) if they had 5% or fewer blasts and tri-lineage recovery after one
course of induction chemotherapy. Overall survival (OS) was determined both from time of
study entry or from end of course 1. Event-free survival (EFS) was defined as the time from
study entry until death, induction failure, or relapse. The Wilcoxon rank sum test was used
to determine the significance between differences in medians of groups. The Cox
proportional hazards model was used to evaluate the impact of miR-155 expression level as
a predictor of clinical outcome in the context of prognostic factors (FLT3/ITD, NPM1,
CEBPA mutations, treatment arm, risk group, age, WBC) and molecular risk groups using
them as covariates in both univariate and multivariate models.

3 Results
3.1 miR-155 expression correlates with high-risk AML
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Among 1,022 patients enrolled on AAML0531, 233 patients had NK-AML, and 198 of
these patients had diagnostic material available to assess miR-155 expression by quantitative
RT-PCR. miR-155 expression varied over 4 log10 (10,000-fold change), with a median
expression level of 0.825 (range 0.043–25.630). For purposes of clinical correlation, the
study population was divided into four quartiles based on miR-155 expression, and
expression levels were correlated with demographics, pretreatment laboratory findings, and
disease characteristics across the four quartiles (Table 1). Median expression for quartiles 1–
4 was Q1: 0.309 (range 0.043–0.439), Q2: 0.575 (range 0.448– 0.824), Q3: 1.213 (range
0.826–1.636), and Q4: 3.036 (range 1.637– 25.630) (Fig. 1A). MiR-155 expression was
highly associated with molecular prognostic factors. FLT3/ITD, NPM1, CEBPA, and WT1
mutations were detected in 37, 15, 24, and 11% of evaluable samples, respectively. There
was a statistically significant increase in FLT3/ITD prevalence with increasing miR-155
expression by quartiles (9, 24, 59, and 69% in Q1–Q4, respectively; P < 0.001; Fig. 1B),
whereas no definitive trend in prevalence was observed for NPM1,CEPBPA, or WT1
mutations. Patient samples were stratified into low-risk 67/198 (34%), standard-risk 83/198
(42%), and high-risk 48/198 (24%) according to FLT3/ITD, NPM1, CEBPA, and WT1
mutations.29 There was a direct association between miR-155 expression and prevalence of
high-risk AML (P < 0.001; Fig. 1C). The prevalence of standard-risk disease decreased with
each quartile (P = 0.008; Fig. 1C). There was no significant trend in prevalence by quartile
for low-risk disease (P = 0.041; Fig. 1C).
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3.2 High miR-155 expression correlates with induction failure and worse survival in NKAML
Induction response rates to initial chemotherapy was correlated with miR-155 expression
level. Patients with high miR-155 expression had induction failure rates of 54% versus 17%
for patients with lower miR-155 expression (P < 0.001). As FLT3/ITD is overrepresented in
high miR-155 expressing cases and FLT3/ITD is associated with higher induction failure, we
evaluated the remission induction rate in patients without FLT3/ITD. Similar to the entire
cohort, FLT3/ITD-negative patients with high miR-155 expression had higher induction
failure rates as compared to patients with lower miR-155 expression, 53 versus 14%,
respectively (P = 0.002; Fig. 2). FLT3/ITD-positive patients with lower miR-155 expression
had an induction failure rate of 24 versus 55% for patients with high miR-155 expression (P
= 0.008). These data demonstrate that high miR-155 expression is associated with higher
induction failure rates regardless of FLT3/ITD mutation status.
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We then evaluated the impact of miR-155 expression on survival. Initial evaluation of
survival by quartiles demonstrated that patients with miR-155 expression in Q1–Q3 (low
expression) had significantly better outcomes as compared with patients with the highest
miR-155 expression (Q4) (Fig. 3A). Consequently, OS and EFS were compared for the high
miR-155 expression (Q4) versus lower miR-155 expression (Q1–Q3). Actuarial OS at 3
years was 51 ± 14% for patients with high miR-155 expression (Q4) as compared with 75
± 7% for patients with lower expression (Q1–Q3, P = 0.002; Fig. 3C). Corresponding EFS
from study entry for those with high and low miR-155 expression was 32 ± 13% versus 59
± 8% (P < 0.001; Fig. 3D).
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In order to evaluate whether miR-155 expression might be an independent prognostic factor
in NK-AML, we performed a multivariate Cox regression analyses to evaluate the impact of
miR-155 expression level as a predictor of clinical outcome in the context of known
prognostic factors including FLT3/ITD, NPM1, CEBPA mutation status, age, and total white
blood cell count (Table 2). In this multivariate model, high miR-155 expression retained
prognostic significance for OS (HR 1.92, 95%CI 1.10–3.36, P=0.022) and EFS (HR 1.75,
95%CI 1.10–2.80, P = 0.019).

4 Discussion
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Pediatric AML accounts for one fourth of acute leukemias in children, but leads to nearly
half of all leukemia deaths. While several molecular alterations in AML predict clinical
outcomes, there are very few genomic alterations that are used to determine therapy. In
normal hematopoietic cells, miR-155 plays an important role in immune cell function by
regulating inflammation and immunological memory.30 MiRNAs control normal myeloid
cell development and aberrant expression of miRNAs play key roles in myeloid
malignancies.30 MiR-155 is an oncomiR that contributes to leukemogenesis.21,22 This study
demonstrates the association of high miR-155 expression with poor response to induction
chemotherapy and poor EFS and OS in pediatric leukemia patients.
While other investigators have explored the role of microRNA in pediatric AML, none have
identified specific microRNA of prognostic significance that could be used to guide therapy
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decisions. For example, Daschkey et al.31 identified clusters of miRNA that were
differentially expressed in specific cytogenetic subtypes of pediatric AML, specifically,
MLL rearranged and core binding factor AML. In this setting, differential miRNA
expression was evaluated solely as a means of distinguishing between various cytogenetic
subtypes rather than identifying miRNA expression levels of prognostic significance. Emmrich et al. explored the functional biology of miR-9 in pediatric patients with t(8;21) AML.
While differential expression of miR-9 did not seem to have prognostic significance in
children with t(8;21) AML, miR-9 expression levels were markedly reduced in t(8;21)
patients versus children with other AML subtypes. In addition, when miR-9 was ectopically
expressed in both AML cell lines as well as primary patient samples with t(8;21), it was
noted that differentiation along the monocytic lineage could be induced.32 Lastly, while
Zhang et al.33 identified specific miRNA profiles that correlated with a higher incidence of
relapse in pediatric acute lymphoblastic leukemia (ALL), to our knowledge, similar findings
have not been reported in pediatric AML.
We demonstrate significant variability of miR-155 expression in children with NK-AML.
Increased miR-155 expression was directly associated with adverse molecular risk factors
(FLT3/ITD+) and high-risk disease and inversely associated with low and standard-risk
disease. CR rates were consistently low for patients with high miR-155 expression across the
entire cohort, which appeared to be unrelated to the presence of FLT3/ITD mutations. We
further showed an association between miR-155 expression and clinical outcome, and in
multivariate analysis that included clinically relevant risk factors, we demonstrate that high
miR-155 expression remained an independent predictor of adverse outcome after controlling
for FLT3/ITD, NPM1, or CEBPA mutations.
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Our findings in pediatric AML patients are similar to observations in adult NK-AML
patients where miR-155 expression levels correlated with somatic mutation status and
clinical outcome. Specifically, Faraoni et al.34 examined the expression level of miR-155 in
48 adult patients with newly diagnosed NK-AML and noted increased miR-155 expression
in patients with FLT3/ITD when compared when patients with wild-type FLT3. In a larger
study of 363 newly diagnosed adult NK-AML patients, an increased prevalence of
FLT3/ITD mutations was found in bone marrow and/or peripheral blood blasts of patients
with high miR-155 expression.19 Similar to our findings, this study also demonstrated that
high miR-155 expression as compared with low mir-155 expression was associated with
shorter disease-free survival (27 vs. 55%, respectively; P < 0.01) and OS (28 vs. 57%,
respectively; P < 0.01), which remained significant after adjustment for FLT3/ITD status. In
addition, among patients less than 60 years of age with high mir-155 expression, the
likelihood of achieving CR was significantly reduced when compared with patients with low
miR-155 expression (76 vs. 90%; P = 0.03).19
While several studies have demonstrated the negative prognostic significance of high
miR-155 expression in adults with NK-AML, our analysis is the first study to demonstrate
that high miR-155 expression is an independent negative prognostic factor in pediatric AML
patients.
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Despite strong correlations between increased miR-155 expression and poor outcomes, our
mechanistic understanding of how miR-155 contributes to AML remains limited. Recently,
signaling downstream of FLT3/ITD was shown to directly induce increased miR-155
expression through activation of NF-KB (p65) and STAT5 transcription factors.35 Whether a
similar pathway exists in patients with high miR-155 expression who lack FLT3/ITD
mutations remains to be determined. HOXA9 regulates miR-155 expression in normal
hematopoietic cells36 and HOXA9 is highly expressed in subsets of adult AML patients,
where it contributes to leukemogenesis,37 consequently HOXA9 may also regulate high
expression of miR-155 in leukemia cells.35,38,39 In FLT3/ITD AML cells, miR-155 targets
the myeloid transcription factor PU.1 to influence proliferation, differentiation, and
apoptosis of leukemic cells.35 Genes whose expression correlates with miR-155 expression
in adult NK-AML have been identified, but their specific role in AML pathogenesis or
whether they are directly targeted by miR-155 has not been fully determined.19 Validated
miR-155 targets include genes that impact leukemogenesis, inflammation, and act as tumor
suppressors.40 In myelodysplastic syndromes, miR-155 targets SH2 domain-containing
inositol 5′-phosphatase 1 (SHIP-1), which inhibits the PI3K/AKT signaling pathway, and in
turn regulates myeloid cell proliferation and survival.41 Intriguingly, recent observations
suggest that while increased miR-155 expression in FLT3 ITD cases is oncogenic, increased
miR-155 in wild-type FLT3 AML cell lines may act as a tumor suppressor to promote cell
differentiation and apoptosis. These observations suggest the cellular context of other
genomic alterations may influence the effects of miR-155 on leukemogenesis.42,43 In
keeping with this observation, in murine models, miR-155 overexpression in hematopoietic
stem cells leads to a myeloproliferative disorder that does not progress to acute leukemia,
suggesting additional mutations are involved in AML progression.22 Nonetheless, our
clinical data demonstrate that high miR-155 expression, regardless of mutation status in NKAML, correlates with poorer EFS and OS.
In conclusion, high miR-155 expression is an adverse prognostic factor in both pediatric and
adult NK-AML patients and correlates with FLT3/ITD mutation status. High miR-155
expression is an independent predictor of worse EFS and OS. While several miR-155 target
genes have been identified, the functional role of miR-155 in AML pathogenesis warrants
additional investigations as does the identification of the optimal cut-point for defining high
miR-155 expression. The ability to target small noncoding RNAs for therapies in cancers is
currently in preclinical development and in early clinical trials.44–46 Decreasing miR-155
function with antogomirs may provide therapeutic benefit to certain subsets of AML,
including FLT3/ITD-positive AML patients and high miR-155 expression.25,26
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CI

Confidence Interval

CR

complete remission

EFS

event-free survival

FC

Fold Change

HR

Hazard Ratio

miRNA

miR, microRNA

MLL

mixed lineage leukemia

NK-AML

normal karyotype acute myeloid leukemia
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overall survival
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Reverse Transcription Polymerase Chain Reaction
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Figure 1.

Distribution of miR-155 expression levels per quartile. (A) Log-fold change. (B) Prevalence
of mutations. (C) Disease risk group classification
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Figure 2. Induction failure rates for all patients, FLT3/ITD-positive patients and FLT3/ITDnegative patients for those with high miR-155 expression levels (Q4) vs. low miR-155 expression
levels (Q1–Q3)
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Figure 3.
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Association between miR-155 expression levels and long-term clinical outcomes. (A) OS
from study entry by miR-155 expression level quartiles Q1 vs. Q2 vs. Q3 vs. Q4. (B) EFS
from study entry by miR-155 expression level quartiles Q1 vs. Q2 vs. Q3 vs. Q4. (C) OS for
patients with high miR-155 expression levels (Q4) vs. low miR-155 expression levels (Q1–
Q3). (D) EFS for patients with high miR-155 expression levels (Q4) vs. low miR-155
expression levels (Q1–Q3)
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